Analysts’ Recommendations for Boston Scientific Stock
Analyst recommendations for Boston Scientific
Boston Scientific (BSX) offers minimally invasive technologies for the treatment of a wide range of diseases. The company operates in three business segments: MedSurg, Cardiovascular, and Rhythm Management.
Boston Scientific reported solid growth in 2Q17, which was reported on July 27, 2017. Let’s see how the analysts’ recommendations and target prices stand for the BSX stock over the next 12 months.
Interested in BSX? Don't miss the next report.
Receive e-mail alerts for new research on BSX
According to the recommendations of 24 brokerage companies surveyed by Reuters, ~75% of the analysts provided a “buy” rating for BSX stock. The stock was given “hold” ratings by 25% of the analysts. However, there were no “sell” recommendations for BSX.
The recommendation summary on Boston Scientific stock is illustrated in the chart above. On September 27, 2017, the consensus 12-month target price for BSX stock was $31.02, which represents a return potential of ~8.2% compared to the closing price of $28.68 on September 26, 2017.
Investors interested in diversified exposure to Boston Scientific can consider the Vanguard Growth ETF (VUG). BSX accounts for ~0.38% of the total holdings of VUG.
Analysts’ target prices and revised recommendations
On September 25, 2017, Stifel Nicolaus reissued its “buy” rating on BSX stock. It has a price target of $32.00 per share on BSX stock, which represents an upside potential of ~11.6% over the next 12 months. On September 1, 2017, Royal Bank of Canada also reaffirmed its “buy” rating on the stock. It has a target price of $31.00 per share on BSX stock.
On September 27, 2017, peers Intuitive Surgical (ISRG), Medtronic (MDT), and Zimmer Biomet Holdings (ZBH) have average broker target prices of $1,016.20, $91.11, and $135.65, respectively. These targets represent returns of -0.40%, 17.5%, and 17.3%, respectively, over the next 12 months.